Skip to content


  • Oral presentation
  • Open Access

14.2 Causes of early death in juvenile onset systemic lupus erythematosus (JSLE)

  • 1,
  • 2,
  • 3,
  • 4,
  • 5,
  • 6,
  • 7,
  • 11,
  • 9,
  • 8,
  • 10 and
  • 1
Pediatric Rheumatology20086 (Suppl 1) :S29

  • Published:


  • Nephrotic Syndrome
  • Thromboembolic Event
  • Organ Involvement
  • Paediatric Rheumatology
  • Intravenous Cyclophosphamide


To describe the causes of death occurring within the first month following the diagnosis of JSLE in order to prevent them.


Retrospective study of causes of early death in JSLE patients during the period 1995 – 2006 conducted on behalf of Paediatric Rheumatology International Trials Organization (PRINTO). All the patients fulfilled the American College of Rheumatology (ACR) criteria for the diagnosis of SLE, and were diagnosed before 16 years of age.


Death was recorded in 5 girls and 1 boy including three non Caucasian patients, aged 6 to 16 years. Initial SLE manifestations comprised at least three organ involvement, including at least two major organ involvement: central nervous system (4 patients), kidney (5 patients), pancreas (2 patients), hematopoietic system (3 patients), heart (1 patient), skin (2 patients), and joints (3 patients). Despite administration of oral and pulsed steroids, associated twice with intravenous cyclophosphamide, SLE activity remained uncontrolled in all the patients. Death resulted from SLE organ failure either alone in 2 patients (pancreatitis: 1 patient, neurolupus: 1 patient), either associated with thrombotic event (catastrophic antiphospholipid syndrome: 2 patients, pulmonary thromboembolism: 1 patient with nephrotic syndrome) and/or infection (paravertebral abcess: 1 patient, pneumococcal sepsis: 1 patient).


Despite prompt diagnosis and management, death may occur at presentation of juvenile-onset SLE. Half of them resulted from thromboembolic event in patients with nephrotic syndrome or APL. These features suggest that prompt prophylactic anticoagulation may be beneficial in patients with severe SLE multiorgan involvements associated with risk factors of thromboembolic event.

Authors’ Affiliations

Necker Hospital, Paris, France
Saint Jacques Hospital, Besançon, France
SGPGI, Lucknow, India
La Paz Hospital, Madrid, Spain
Garrahan Hospital, Buenos Aires, Argentina
Universitade do Estato do Rio de Janeiro, Rio de Janeireo, Brazil
University children's hospital, Ljubljana, Slovenia
Hacettepe university, Ankara, Turkey
Jasklov Hospital, Mumbai, India
Hospices civils de Lyon, Lyon, France
IPPMG, Rio Do Janeiro, Brazil


© Bader-Meunier et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.